{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221593","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-05-13T20:05:18+00:00","discovered_at":"2026-05-13T20:07:00.323726+00:00","generated_at":"2026-05-13T22:12:38.506705+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured","bullets":["Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.","RAINIER trial on track for completion and Phase 2 dose selection by year-end 2026.","Q1 2026 cash position $14.5M; raised $0.9M net under SEPAs; secured new $60M SEPA with Yorkville.","Jeff Lamothe appointed CEO; Marvin White transitions to Executive Chair.","Leadership believes the $60M facility extends capital access into 2029 through key catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221593","json":"https://secwatch.observer/filing/0001193125-26-221593.json","markdown":"https://secwatch.observer/filing/0001193125-26-221593.md","text":"https://secwatch.observer/filing/0001193125-26-221593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526221593/0001193125-26-221593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526221593/apvo-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:12:38.506705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}